Andrew Farnum

Andrew Farnum has had a long and successful career in the medical research industry. Andrew began their career as an investment manager at the Children's Investment Fund Foundation. Andrew then moved on to the Bill & Melinda Gates Foundation, where they served as the director of the Gates Foundation Strategic Investment Fund. In this role, they were responsible for leading the Gates Foundation's $2 billion strategic investment fund.

In January 2018, Farnum joined the Board of Directors of the Bill & Melinda Gates Medical Research Institute. Andrew served in this role for three years before being appointed as the CEO of Variant Bio in December 2020.

Tom Rush - Chief R&D Officer, Gregory Tranah - VP, Medical Biology, and Holly Vance - General Counsel report to Andrew Farnum.